Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Out-licensing
- View
Aldose Reductase Inhibiting Agents
Aldose reductase inhibitors available for license.
Full description
Alcon is offering for license, spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase and additional novel compositions to treat glucose toxicity and complications arising from diabetes.
Development status
Preclinical
Patent information
US4537892 issued 27-Aug-1985 US4864028 issued 05-Sep-1989 US5070100 issued 03-Dec-1991 US5153211 issued 06-Oct-1992 US5151544 issued 29-Sep-1992 US5521208 issued 28-May-1996
Type of business relationship sought
Available for license.
Licensing contact
Mr. Thomas G. Capetan
Vice President
Licensing / Business Development
Vice President
Licensing / Business Development
Company details
Alcon
Alcon is the worldwide leader in the discovery, development and manufacture of innovative ophthalmic products and technologies.
Alcon is the worldwide leader in the discovery, development and manufacture of innovative ophthalmic products and technologies.
Related reports
Are you looking for reports related to this particular subject. Our Reports section is the best place to start.
Related items
- Phytohealth Corporation: PH3 (PHN031, PHN033) - For osteoporosis and diabetic vascular complications
- A Battery of Genetic Biomarkers of Severe Outcome in Patients with Elevated Triglyceride Levels
- 1,2,4-Benzothiadiazine derivatives
- Biocompatible and biodegradable nanoparticles
- SNP-Disease Association via a Comprehensive DNA Resource
Related categories
- Industry sector
- Pharmaceutical
- Pharmaceutical / Prescription
- Therapeutic target
- Metabolism / Diabetes type I
- Metabolism / Diabetes type II
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us